• Review • Previous Articles     Next Articles

Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma

ZHANG Lin-yuan1, ZHANG Ming2, DA Jun2   

  1. 1.Clinical Medicine, Undergraduate of Grade 2012, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2.Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
  • Online:2016-12-28 Published:2016-12-29


The efficacy of mTOR inhibitor everolimus for targeted first-line, second-line, and sequential treatments of renal cell carcinoma is investigated and adverse reactions are summarized through introducing the PI3K/AKT/mTOR signaling pathways and their roles in renal cell carcinoma. It has been shown that everolimus alone has poor efficacy in first-line treatment, supporting the strategy mentioned in renal cell carcinoma treatment guidelines that everolimus can be used in second-line treatment after unsuccessful treatment with anti-angiogenic tyrosine kinase inhibitors. First-line treatment with everolimus plus other drugs requires further investigation. Everolimus has generally good tolerance, but the problem of high rate of grade 3-4 adverse reactions still needs to be solved.

Key words: PI3K/AKT/mTOR signal pathway, renal cell carcinoma, targeted therapy, everolimus, clinical efficacy, adverse reactions